Iovance Biotherapeutics, Inc.
IOVA
Rankning i aktier
#2897
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Aktiekurs
$14.13
Senast synkroniserad: 2026-10-19
Marknadsvärde
$6.40B
Förändring (1 dag)
3.74%
Förändring (1 år)
509.05%
Land
US
Handel Iovance Biotherapeutics, Inc. (IOVA)
Kategori
Healthcare
EPS för Iovance Biotherapeutics, Inc. (IOVA)
EPS per June 2026 TTM: $-0.73
Enligt Iovance Biotherapeutics, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-0.73. Vid slutet av 2023 hade bolaget ett EPS på $-1.89, en minskning jämfört med EPS från 2022 som var $-2.49.
EPS-historik för Iovance Biotherapeutics, Inc. från 2008 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $-0.73 | -42.97% |
| 2024 | $-1.28 | -32.28% |
| 2023 | $-1.89 | -24.10% |
| 2022 | $-2.49 | 11.66% |
| 2021 | $-2.23 | 18.62% |
| 2020 | $-1.88 | 25.33% |
| 2019 | $-1.50 | 18.11% |
| 2018 | $-1.27 | -9.93% |
| 2017 | $-1.41 | 46.88% |
| 2016 | $-0.96 | 54.84% |
| 2015 | $-0.62 | 29.17% |
| 2014 | $-0.48 | -81.54% |
| 2013 | $-2.60 | -37.20% |
| 2012 | $-4.14 | -87.77% |
| 2011 | $-33.84 | 1,275.61% |
| 2010 | $-2.46 | 14,370.59% |
| 2009 | $-0.02 | -63.91% |
| 2008 | $-0.05 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | -2,472.60% |
US
|
|
| $-7.98 | 993.15% |
US
|
|
| $-5.29 | 624.66% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,900.00% |
NL
|
